Abstract
AbstractThe non-perfused volume (NPV) is an important indicator of treatment success immediately after prostate ablation. However, visualization of the NPV first requires an injection of MRI contrast agents into the bloodstream, which has many downsides. Purpose of this study was to develop a deep learning model capable of predicting the NPV immediately after prostate ablation therapy without the need for MRI contrast agents. A modified 2D deep learning UNet model was developed to predict the post-treatment NPV. MRI imaging data from 95 patients who had previously undergone prostate ablation therapy for treatment of localized prostate cancer were used to train, validate, and test the model. Model inputs were T1/T2-weighted and thermometry MRI images, which were always acquired without any MRI contrast agents and prior to the final NPV image on treatment-day. Model output was the predicted NPV. Model accuracy was assessed using the Dice-Similarity Coefficient (DSC) by comparing the predicted to ground truth NPV. A radiologist also performed a qualitative assessment of NPV. Mean (std) DSC score for predicted NPV was 85% ± 8.1% compared to ground truth. Model performance was significantly better for slices with larger prostate radii (> 24 mm) and for whole-gland rather than partial ablation slices. The predicted NPV was indistinguishable from ground truth for 31% of images. Feasibility of predicting NPV using a UNet model without MRI contrast agents was clearly established. If developed further, this could improve patient treatment outcomes and could obviate the need for contrast agents altogether.Trial Registration Numbers Three studies were used to populate the data: NCT02766543, NCT03814252 and NCT03350529.
Funder
University of Turku (UTU) including Turku University Central Hospital
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. NCCN. NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer 2022. 2022; Available from: https://doi.org/10.1016/B978-1-4557-2865-7.00084-9
2. Gravas S, Cornu JN, Gacci M, Gratske C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) 2020. European Association ofUrology Guidelines 2020 Edition [Internet] Arnhem, The Netherlands:European Association of Urology Guidelines Office; 2020 [Internet]. 2020; Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
3. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura K, Costa D, Persigehl T, Pantuck A, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol. 2021;205:769–79.
4. Lumiani A, Samun D, Sroka R, Muschter R. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urologic Oncology: Seminars and Original Investigations [Internet]. Elsevier Inc.; 2021;000:0–7. Available from: https://doi.org/10.1016/j.urolonc.2021.04.022
5. Anttinen M, Mäkelä P, Suomi V, Kiviniemi A, Saunavaara J, Sainio T, Horte A, Eklund L, Taimen P, Sequeiros R, Boström P. Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scand J Urol England. 2019;53:295–302.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献